Analysis of the effect of recombinant humanendostatin combined with anlotinib regimen in the second-line treatment of non-small cell lung cancer

ZHOU Chuanjiang; MA Chuansheng; SHOU Yongxiang

doi:10.3969/j.issn.1674-4136.2021.05.018

Home>Articles>Analysis of the effect of recombinant humanendostatin combined with anlotinib regimen in the second-line treatment of non-small cell lung cancer

DOI: 10.3969/j.issn.1674-4136.2021.05.018

Analysis of the effect of recombinant humanendostatin combined with anlotinib regimen in the second-line treatment of non-small cell lung cancer

ZHOU Chuanjiang

MA Chuansheng

SHOU Yongxiang

Machine-generated Keywords：

Publication Date：2021-10-20

Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)

Pages：4( 509-512 )

Chinese Journal of Surgical Oncology

ISTIC

ISSN：1674-4136

Year, Vol.(Issue)：2021,13(5)